Effect of antenatal administration of thyrotrophin releasing hormone on fetal flow velocity waveforms

Rekha Bajoria, Konstantinos D Stagiannis, Nicholas M Fisk

Abstract

Aim—To determine whether antenatal administration of thyrotrophin releasing hormone (TRH), to promote lung matura- tion, alters blood flow through the fetal middle cerebral, umbilical artery, or ductus arteriosus and through the maternal uterine arteries.

Methods—The effect of transplacentally administered TRH on the fetal circulation was prospectively evaluated in 30 patients between 24 and 34 weeks’ gestation. TRH (400 µg) was given to the mother intrave- nously either as a bolus or an infusion. Fetal effects were determined by measuring the maximum velocity and pulsatility index (PI) in middle cerebral artery, ductus arteriosus, uterine artery and umbilical artery Doppler waveforms. Measurements were made immediately before, and 10 and 60 minutes after maternal TRH administration.

Results—Intravenous injection of TRH had no significant effect on PI in the uterine, umbilical, or middle cerebral artery and the ductus arteriosus within 60 minutes of administration in either group.

Conclusion—The antenatal use of TRH in conjunction with steroids for fetal lung maturity does not affect utero-placental or fetal haemodynamic variables, as measured by Doppler. These findings, therefore, do not support the suggestion that antenatal intravenous administration of TRH either as bolus or infusion may have immediate adverse vascular effects in the fetus.

(Arch Dis Child 1997;77:F127–F130)

Keywords: thyrotrophin releasing hormone; fetal middle cerebral artery; ductus arteriosus; utero-placental circulation; fetal Doppler

Respiratory distress syndrome (RDS) is a major cause of neonatal mortality and morbidity.1 Transplacental glucocorticoids reduce the incidence of RDS by only 50% and attention has now focused on antenatal administration of thyrotrophin releasing hormone (TRH) together with glucocorticoids to enhance surfactant synthesis and release.2 Meta-analysis shows that this strategy significantly reduces the incidence of RDS, the need for oxygen therapy, and the frequency of bronchopulmonary dysplasia.3

Apart from its hypophysiotrophic effect, TRH functions as a ubiquitous neurotransmitter, and is known to cause cerebral haemodynamic effects in experimental animals and in humans,4 seemingly via sympathetic activation and increased catecholamine production.5 Before TRH becomes widely used in clinical practice, it is important to know whether it influences fetal blood flow. Given the increasing use of Doppler monitoring in pregnancies at risk of preterm delivery, the haemodynamic effects of maternally administered TRH need to be determined. This is particularly important as TRH increases maternal blood pressure6 and suppresses endogenous prostaglandin synthesis,7 both of which are essential for regulation of ductal patency. As the rationale behind antenatal use of TRH for enhancement of fetal lung maturation is based on the assumption that it crosses the placenta freely to stimulate fetal pituitary–thyroid axis,8 9 we speculate that such treatment may also cause ductal constriction and reduced placental perfusion. To test this hypothesis, we studied the effect of maternally administered TRH on uterine artery (UPA), fetal middle cerebral artery (MCA), ductus arteriosus (DA) and umbilical artery (UA) using colour Doppler. Furthermore, as the findings of the recent largest, multicentric double blind trial10 raised concern that the beneficial effect of antenatally administered TRH may depend on its mode of administration, we also compared the effect of TRH on fetal haemodynamics when given intravenously as a bolus or as infusion.

Methods

In this prospective observational study, fetal haemodynamic changes were determined in 40 mothers following antenatal administration of TRH. The study was conducted in a tertiary referral centre in 1994.

Patients with singleton fetuses between 24 and 34 weeks of gestation who where at risk of preterm delivery and in whom TRH administration was clinically indicated, were recruited. The gestational age was determined by ultrasound scan between 18 and 20 weeks. Mothers with multiple pregnancy, antepartum haemor- rhage, pre-eclampsia or evidence of fetal com- promise did not enter the study. Fetal wellbeing was assessed clinically by cardiotocography and fetal growth and liquor volume on ultrasonographic examination. Patients already in well established labour (cervical dilatation > 3 cm and/or uterine contractions > 1 in 10
Table 1  Clinical findings and perinatal outcome

<table>
<thead>
<tr>
<th></th>
<th>TRH (bolus) (n=14)</th>
<th>TRH (infusion) (n=16)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal age (years)</td>
<td>28.5 (18 to 39)</td>
<td>32 (21 to 36)</td>
<td>NS</td>
</tr>
<tr>
<td>Parity</td>
<td>2 (1 to 4)</td>
<td>2 (0 to 7)</td>
<td>NS</td>
</tr>
<tr>
<td>Gestational age: At entry to study (weeks)</td>
<td>30.8 (27 to 34.3)</td>
<td>30.2 (26 to 34.3)</td>
<td>NS</td>
</tr>
<tr>
<td>At delivery (weeks)</td>
<td>38.0 (31.4 to 40.5)</td>
<td>36.6 (28 to 41.2)</td>
<td>NS</td>
</tr>
<tr>
<td>Mode of delivery: SVD</td>
<td>10</td>
<td>10</td>
<td>NS</td>
</tr>
<tr>
<td>LSCS</td>
<td>6</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Birthweight (g)</td>
<td>2985 (1125 to 3904)</td>
<td>2814 (1024 to 3528)</td>
<td>NS</td>
</tr>
<tr>
<td>Apgar score at: 1 min</td>
<td>8 (6 to 10)</td>
<td>9 (6 to 9)</td>
<td>NS</td>
</tr>
<tr>
<td>10 min</td>
<td>10 (8 to 10)</td>
<td>10 (9 to 10)</td>
<td>NS</td>
</tr>
<tr>
<td>Cord arterial pH</td>
<td>7.237 (7.18 to 7.30)</td>
<td>7.305 (7.09 to 7.4)</td>
<td></td>
</tr>
<tr>
<td>Mild</td>
<td>6</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Severe</td>
<td>1</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

Results

Of 40 patients studied, 10 were excluded because Doppler waveforms could not be obtained after treatment: in three, because of increasing uterine activity, in four due to technical difficulties, and in a further three because patients found the procedure uncomfortable. In 30 patients where a complete data set was obtained, 16 received TRH as a bolus and 14 as an infusion. Clinical features of both groups are shown in the table 1. Essentially, the maternal age, gestational age at recruitment, delivery, birthweight, Apgar score and the incidence of RDS were similar in both groups. At time of the study, one fetus in the bolus group had intrauterine growth retardation with oligohydramnios (growth along 10th centile; amniotic fluid index <4 cm), with no evidence of redistribution. The median time interval between steroid injection and Doppler studies was 40 minutes (range 20–120).

The baseline PI of uterine artery and fetal vessels (MCA, DA, and umbilical artery) were all within 2 SD of the mean for gestational age for appropriately grown fetuses. There was no significant change in the pulsatility index and maximum flow velocity of MCA and DA during and after intravenous TRH administration as a bolus or as an infusion (fig 1). Similarly, no significant effects were found in the PI for the uterine artery and umbilical artery before and after treatment in either group (fig 2).

Conclusion

This study indicates that antenatal administration of TRH either as bolus or infusion has no
discernible effect on utero-placental perfusion and fetal blood flow through the umbilical, cerebral, and ductal circulation. We used the indices of PI and Vmax in Doppler flow velocity waveforms from these vessels to determine the effect of TRH. These parameters, however, provide limited information because they are indirect methods of determining changes in blood flow. Direct methods of quantifying volume flow were not used, as they are generally considered to be inaccurate due to cumulative poor reproducibility of vessel diameter, estimated weight, and velocity. Moreover, PI and maximum velocity have been widely used as reproducible parameters in clinical practice and in several research studies to determine the effect of prostaglandin synthase inhibitors on fetal vasculature.14 15

Our data suggest that the increase in cerebral blood flow seen in adults17 after TRH does not occur in fetuses. Similarly, direct administration of TRH to the fetal lamb improves cardiovascular function at birth secondary to increased circulating concentrations of catecholamines.6 In contrast, our study showed no effect of transplacental TRH on fetal blood flow. A recent study in human fetuses similarly showed that intravenous infusion of TRH fails to alter fetal blood flow through the middle cerebral artery.18 Those authors found a significant alteration in cardiac flow velocity 45 minutes after TRH administration as an intravenous infusion, which may have been an effect of TRH mediated fetal thyroxine release rather than of TRH itself. In our study we attempted to record the direct effect of TRH on fetal cerebral haemodynamics by measuring the PI at 10 minutes and again at one hour after TRH administration. We chose this time period because the maximum placental transfer of TRH is expected to occur within 10 minutes of administration due to its half life of 5.5–7 minutes.19

TRH increases peripheral resistance, presumably due to the release of catecholamines8 and therefore might affect uterine blood flow. However, we failed to demonstrate any change in the uterine artery blood flow after prenatal treatment with TRH. One explanation for this may be that TRH causes a transient rise in the maternal blood pressure which is not sustained long enough1 to alter uterine artery blood flow. TRH can cross the placenta and inhibit endogenous prostaglandin secretion, which is essential for maintenance of ductal patency19 and therefore might also affect fetal ductal flow. We also failed to observe any change on fetal ductal blood flow following intravenous administration of TRH. Failure to show a change in fetal haemodynamics after administration of TRH might possibly be attributed to concomitant steroid use. Animal studies indicate that glucocorticoids can constrict the ductus arteriosus by suppressing endogenous prostaglandin production.20 Although evidence in human fetuses is inconclusive,21 a transient, mild constriction of the ductus arteriosus has been documented within 4 to 5 hours of the first injection of betamethasone or 36 hours after three to four courses of corticosteroids.22 In
contrast in this study, all Doppler measurements were made within an hour of first dose of betamethasone. Therefore, it is unlikely that any effect of TRH on fetal waveforms was masked by concomitant steroid use. Furthermore, given the route of administration and feto-maternal ratio of 0.33, therapeutic concentrations of steroids are unlikely to have been attained in the fetal circulation within 60 minutes of maternal administration.

The lack of physiological response of the fetus to TRH could be due to one of the following reasons. Firstly, TRH might be present in the fetal circulation at subthreshold concentrations. Although we did not measure the concentration of TRH in the maternal or fetal circulation, this seems unlikely because a similar dose of TRH as has been used before by other investigators, was used in our study. A higher fetal concentration of TRH may be needed to elicit a cardiovascular response compared with its endocrine effect. Secondly, rapid elimination of TRH from the fetal circulation might explain its lack of neurotrophic response. Although no data are available on the pharmacokinetics of TRH on the fetal circulation, the presence of relatively high concentrations of endogenous TRH in the fetal blood instead raises the possibility of impaired clearance. Another explanation regarding the lack of a cardioetiological effect of TRH could be due to the inability of the human fetus to mount a catecholaminergic response between 24 to 34 weeks of gestation. Failure to demonstrate any change in fetal heart rate is consistent with this proposition. Notwithstanding, the human fetus is capable of mounting a response to exogenous stimuli by secreting endorphins and catecholamines from 24 weeks of gestation. Alternatively, if extrahypothalamic TRH receptors were absent in the human fetus, this would explain the lack of a significant effect on fetal blood flow velocity. Although no data are available on the ontogeny of TRH receptors in the human fetal central nervous system, they are present in the fetal pancreas from 15 week's gestation. Lastly, the minimal fetal cardiovascular effects of TRH might be due to its inability to cross the placental membrane. Antenatal administration of TRH elicits fetal thyrotrophic response, but our recent in vitro data indicate that TRH crosses the human placenta sparingly.

This work was supported by a project grant from Action Research.

Effect of antenatal administration of thyrotrophin releasing hormone on fetal flow velocity waveforms

Rekha Bajoria, Konstantinos D Stagiannis and Nicholas M Fisk

Arch Dis Child Fetal Neonatal Ed 1997 77: F127-F130
doi: 10.1136/fn.77.2.F127

Updated information and services can be found at:
http://fn.bmj.com/content/77/2/F127

These include:

References
This article cites 22 articles, 1 of which you can access for free at:
http://fn.bmj.com/content/77/2/F127#BIBL

Email alerting
Receive free email alerts when new articles cite this article. Sign up in the
service
box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Pregnancy (1521)
Reproductive medicine (1433)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/